Literature DB >> 23358426

Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report.

Jee Min Lee1, Urvi N Mehta, Ly H Dsouza, Beverly Ashleigh Guadagnolo, Deborah L Sanders, Kevin B Kim.   

Abstract

We present a patient with metastatic BRAF-mutated melanoma who achieved long-term stabilization of leptomeningeal disease (LMD) with sequential whole-brain radiation therapy and vemurafenib. A 53-year-old woman with melanoma that harbored the BRAF V600E mutation and had that metastasized to multiple lymph nodes, lungs, breast, and subcutaneous tissue had developed symptomatic LMD 16 months after starting vemurafenib treatment despite achieving a substantial response at the existing metastatic sites. Vemurafenib was discontinued for 7 days, she received whole-brain radiation therapy (30 Gy in 10 fractions), and 7 days after completing the radiation therapy, she resumed vemurafenib therapy. The neurologic symptoms improved significantly, and a cerebrospinal fluid examination revealed disappearance of melanoma cells. She remained alive with radiologically stable LMD for at least 18 months after the whole-brain radiation therapy.
© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23358426      PMCID: PMC3880202          DOI: 10.1097/CMR.0b013e32835e589c

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  12 in total

1.  Quantitative study of blood-brain barrier permeability changes after experimental whole-brain radiation.

Authors:  D d'Avella; R Cicciarello; F Albiero; M Mesiti; M E Gagliardi; E Russi; A d'Aquino; F Tomasello; S d'Aquino
Journal:  Neurosurgery       Date:  1992-01       Impact factor: 4.654

2.  Diagnosis and management of leptomeningeal disease.

Authors:  Julie G Walker
Journal:  Clin J Oncol Nurs       Date:  2009-08       Impact factor: 1.027

3.  Leptomeningeal metastases.

Authors:  Jordi Bruna; Marta Simó; Roser Velasco
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

Review 4.  The evolving role of radiation therapy in the management of malignant melanoma.

Authors:  Niloufer Khan; Mohammad K Khan; Alex Almasan; Arun D Singh; Roger Macklis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-12       Impact factor: 7.038

Review 5.  Radiation therapy for leptomeningeal cancer.

Authors:  Minesh Mehta; Kristin Bradley
Journal:  Cancer Treat Res       Date:  2005

6.  Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032.

Authors:  Maria J Sambade; Eldon C Peters; Nancy E Thomas; William K Kaufmann; Randall J Kimple; Janiel M Shields
Journal:  Radiother Oncol       Date:  2011-02-04       Impact factor: 6.280

7.  Prognostic factors for survival in melanoma patients with brain metastases.

Authors:  Michael A Davies; Ping Liu; Susan McIntyre; Kevin B Kim; Nicholas Papadopoulos; Wen-Jen Hwu; Patrick Hwu; Agop Bedikian
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

Review 8.  Leptomeningeal metastases from prostate cancer: an emerging clinical conundrum.

Authors:  George Orphanos; Alexandros Ardavanis
Journal:  Clin Exp Metastasis       Date:  2009-11-11       Impact factor: 5.150

9.  Posterior fossa metastases: risk of leptomeningeal disease when treated with stereotactic radiosurgery compared to surgery.

Authors:  Vitaly E Siomin; Michael A Vogelbaum; Andrew A Kanner; Shih-Yuan Lee; John H Suh; Gene H Barnett
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

10.  Prognostic factors and outcomes in patients with leptomeningeal melanomatosis.

Authors:  Laura Harstad; Kenneth R Hess; Morris D Groves
Journal:  Neuro Oncol       Date:  2008-08-14       Impact factor: 12.300

View more
  16 in total

1.  Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib.

Authors:  David A Liebner; Steven A Walston; Robert Cavaliere; Ciaran J Powers; Eric Sauvageau; Norman L Lehman; Hasel Wayne Slone; Meng Xu-Welliver; Fen Xia; Kari L Kendra
Journal:  Melanoma Res       Date:  2014-04       Impact factor: 3.599

2.  Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy.

Authors:  James J Harding; Christopher A Barker; Richard D Carvajal; Jedd D Wolchok; Paul B Chapman; Mario E Lacouture
Journal:  J Clin Oncol       Date:  2014-01-27       Impact factor: 44.544

Review 3.  Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy.

Authors:  Keiran S M Smalley; Inna V Fedorenko; Rajappa S Kenchappa; Solmaz Sahebjam; Peter A Forsyth
Journal:  Int J Cancer       Date:  2016-04-30       Impact factor: 7.396

4.  Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient.

Authors:  Richard C Wu; William Newman; Liron Patanowitz; Barton F Branstetter; Nduka Amankulor; Ahmad A Tarhini
Journal:  Immunotherapy       Date:  2020-06-22       Impact factor: 4.196

5.  Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors.

Authors:  Maikel Verduin; Jaap D Zindler; Hanneke M A Martinussen; Rob L H Jansen; Sander Croes; Lizza E L Hendriks; Danielle B P Eekers; Ann Hoeben
Journal:  Oncologist       Date:  2017-02-06

Review 6.  Leptomeningeal Metastases: New Opportunities in the Modern Era.

Authors:  Jessica A Wilcox; Min Jun Li; Adrienne A Boire
Journal:  Neurotherapeutics       Date:  2022-07-05       Impact factor: 7.620

7.  Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib.

Authors:  L Peuvrel; M Saint-Jean; G Quéreux; A Brocard; A Khammari; A C Knol; B Dréno
Journal:  J Neurooncol       Date:  2014-08-07       Impact factor: 4.130

Review 8.  Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

Authors:  Christopher J Anker; Kenneth F Grossmann; Michael B Atkins; Gita Suneja; Ahmad A Tarhini; John M Kirkwood
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-06-01       Impact factor: 7.038

9.  Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report.

Authors:  Isabella C Glitza; Cara Haymaker; Chantale Bernatchez; Luis Vence; Michelle Rohlfs; Jessie Richard; Carol Lacey; Rahmatu Mansaray; Orenthial J Fulbright; Renjith Ramachandran; Christopher Toth; Seth Wardell; Sapna P Patel; Scott E Woodman; Wen-Jen Hwu; Laszlo G Radvanyi; Michael A Davies; Nicholas E Papadopoulos; Patrick Hwu
Journal:  Cancer Immunol Res       Date:  2015-07-27       Impact factor: 11.151

Review 10.  Leptomeningeal Disease and the Evolving Role of Molecular Targeted Therapy and Immunotherapy.

Authors:  Katharine Hall Thomas; Robert A Ramirez
Journal:  Ochsner J       Date:  2017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.